Chinese contract research organisation (CRO) Tigermed has formed an alliance with MacroStat, a US-based CRO active in China and specialising in clinical data management.

The deal involves an unspecified capital injection in MacroStat by Tigermed and partner venture capital firm Qiming Venture.

According to Tigermed, the two CROs will pursue “extensive strategic partnership” in clinical trial management, data management and statistical analysis. The alliance will broaden the scope of MacroStat’s operations and “add professionalism to Tigermed’s biostatistics services”, the latter said.

“The win-win co-operation between leading CROs with complementary advantages is conducive to constructing a higher level of CRO service chain and further updating full-service capability, which also opens a fast track to the globalisation of China CROs,” commented Dr Ye Xiaoping, chief executive officer and founder of Tigermed.

The alliance will “not only satisfy global clients with international standards but also power innovative drug development in China, making it possible to streamline the clinical research cycle and considerably reduce drug research and development costs”, added Tigermed vice president Cao Xiaochun.

Both Ye Xiaoping and Cao Xiaochun will join MacroStat’s board of directors along with Hu Xubo, director of Qimimg Venture’s Healthcare Investment Sector. It was a capital injection from Qiming in 2008 that set Tigermed on its current path of rapid expansion and internationalisation, the CRO pointed out.

Last November, Tigermed forged strategic alliances with CROs LSK and OCT in Korea and Russia respectively, with the aim of integrating “resources for the expansion and establishment of a global clinical trial network”.

Macrostat has already established strategic partnerships with a number of multinational pharmaceutical and biotech companies as well as international CROs, becoming their preferred biostatistics vendor, noted Helen Yin, managing director of MacroStat China. MacroStat was founded in Newark, Delaware in 2002. MicroStat China followed in Shanghai three years later.

Most of the company’s customers are from the US and Europe, Helen Yin observed, adding: “With the new capital, MacroStat will further accelerate its development effectively, on the one hand keeping [its] unique advantage in biostatistics, on the other hand extending its business line into clinical trials, so as to provide more extensive and comprehensive services for the pharmaceutical industries”.

Also established in 2002, Tigermed offers a broad range of services including all phases of clinical trials, registration of chemical/biological drugs and medical devices, new drug development, technology transfer, data management, training in Good Clinical Practice and market research.

Therapeutic specialities include oncology, biological vaccines, hepatitis, the digestive system, cardiovascular conditions and infectious diseases. With a staff of 100 serving more than 150 local and global clients, Tigermed has 15 offices in China, one in the US and a liaison office in Europe.